Roivant Indicates Significant Progress in Pipeline with Faster Timelines
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 11 2025
0mins
Source: Benzinga
Long-term Vision: Roivant Sciences outlined its long-term vision during Investor Day, emphasizing accelerated timelines and expanded commercial ambitions for several late-stage programs, with a focus on three major clinical assets.
Brepocitinib Development: The company highlighted strong momentum for brepocitinib, particularly in dermatomyositis, with plans to file a new drug application in early 2026 and a potential commercial launch in early 2027.
Progress on IMVT-1402: Roivant reported advancements in its pipeline, including IMVT-1402, with a recent financing round extending Immunovant's cash runway and updated guidance for topline data in rheumatoid arthritis expected in 2026.
Ongoing Programs and Litigation: Other development programs remain on track, and Roivant is involved in ongoing intellectual property litigation with Moderna, with a U.S. jury trial scheduled for March 2026.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like MRNA with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on MRNA
Wall Street analysts forecast MRNA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRNA is 29.36 USD with a low forecast of 17.00 USD and a high forecast of 63.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
1 Buy
14 Hold
4 Sell
Hold
Current: 45.300
Low
17.00
Averages
29.36
High
63.00
Current: 45.300
Low
17.00
Averages
29.36
High
63.00
About MRNA
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Moderna Partners with Recordati to Advance mRNA-3927 Development
- Strategic Collaboration: Moderna has entered into a strategic partnership with Italy's Recordati to advance the clinical development of its propionic acidemia treatment, mRNA-3927, which is expected to accelerate the global commercialization of the drug.
- Financial Support: Under the agreement, Moderna will receive an upfront payment of $50 million and up to $110 million in development and regulatory milestone payments, significantly enhancing its liquidity and supporting further R&D efforts.
- Clinical Trial Progress: mRNA-3927 is currently undergoing a registrational study that has reached its target enrollment, with pivotal data expected in 2026, laying the groundwork for potential market approval and addressing unmet medical needs.
- Market Potential: Propionic acidemia is a rare and serious inherited metabolic disorder affecting approximately 1 in 100,000 to 150,000 individuals globally, and Moderna's innovative therapeutic approach could fill a significant treatment gap, enhancing the company's competitiveness in the rare disease market.
Continue Reading
Moderna Stock Rises 58% in 2026, Signaling New Opportunities
- Stock Rebound: Moderna's stock has surged 58% in 2026, indicating a potential start of a sustained bull run after several years of stagnant revenue growth.
- Clinical Trial Progress: The intismeran autogene, in combination with Merck's Keytruda, demonstrated a 49% reduction in disease recurrence or death in advanced melanoma patients, highlighting its potential in cancer treatment.
- Product Portfolio Expansion: In addition to intismeran autogene, Moderna is conducting up to eight phase 2 or phase 3 clinical trials, and meaningful progress could significantly enhance the company's market competitiveness and product diversity.
- Long-Term Investment Value: Despite a substantial decline in stock price over the past three years, Moderna's strong performance in 2026 and future clinical and regulatory advancements make it a compelling consideration for long-term investors.
Continue Reading